Tumor-specific mutant protein-derived neoepitope

A tumor-specific mutant protein-derived neoepitope is a peptide produced from a somatic mutation in a tumor cell, which results in a unique sequence not present in normal tissues. These neoepitopes are presented by major histocompatibility complex (MHC) molecules on the tumor cell surface and can be recognized as foreign by the immune system, specifically T cells[1][2][4][7]. Because they result from tumor-specific genetic changes, mutant neoepitopes are highly specific to individual cancers and have minimal expression in healthy tissue, making them ideal and safer therapeutic targets for personalized cancer immunotherapies such as vaccines and adoptive T cell transfer[2][7]. Their immunogenicity depends on efficient presentation by MHC molecules and recognition by T cell receptors, with key predictive features involving structural and biochemical properties distinguishing them from self[4][6]. Neoepitope load correlates with clinical response to some immunotherapies and may serve as a predictive biomarker, though tumor heterogeneity and immune escape remain therapeutic challenges[1][6][7].

Other names

Tumor neoepitopeMutant neoepitopeMutation-derived neoepitopeCancer neoepitopeNeoantigen-derived epitope

Vaccines based on mutation-derived neoepitopes prime T cells against tumor cells presenting those neoepitopes via MHC; Adoptive transfer of T cells or TCR-engineered T cells targeting tumor-specific neoepitopes; Immune checkpoint inhibitors indirectly enhance T cell activity against neoepitope-expressing tumor cells